Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
This review examines the differences in the incidence, spectrum, and mechanisms of activation of opportunistic infections, such as Mycobacterium tuberculosis, in patients with rheumatic diseases treated with the soluble TNF p75 receptor etanercept compared to the 2 anti-TNF-alpha monoclonal antibodies, infliximab and adalimumab.
Dinarello
Charles A
CA
Department of Medicine, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D000068800:Etanercept; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D009169:Mycobacterium tuberculosis / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology*; D012216:Rheumatic Diseases / Q000150:complications / Q000276:immunology; D014376:Tuberculosis / Q000150:complications / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept